Demographic, clinical characteristics and response to treatment in SpA groups.
| Without syndesmophytes n= 92 | Advanced spinal disease n= 99 | Bamboo spine n= 78 | p | |||||
| Age, years˚ | 42.2 ± 8.8 | 51.3 ± 10.2 | 55.5 ± 9.3 | < 0.001* | ||||
| Age at disease onset, years˜ | 25.01 (11) | 36.6 (20) | 33.3 (18) | < 0.001* | ||||
| Male, n (%) | 55 (59.8) | 78 (78.8) | 66 (84.6) | < 0.001* | ||||
| Disease duration, years˜ | 13.8 (5) | 12.3 (15) | 17.6 (13) | < 0.001* | ||||
| Delay in diagnosis, months˜ | 12.02 (43) | 36.01 (89) | 36.01 (100) | 0.013* | ||||
| HLA-B27 positivity/total, n (%) | 21/42 (50) | 31/45 (69) | 16/28 (57) | 0.19 | ||||
| BMI˜ | 26.3 (8) | 29.7 (7) | 29.4 (7) | < 0.001* | ||||
| Smoking (ever), n (%) | 56 (61) | 78 (79) | 58 (74) | 0.019* | ||||
| Hip involvement, positivity/total (%) | 11/84 (13.1) | 34/86 (39.5) | 37/75 (49.3) | < 0.001* | ||||
| Onset | Last | Onset | Last | Onset | Last | p (onset) | p (last) | |
| ESR, mm/h˜ | 21.5 (34) | 12.5 (18) | 25.5 (29) | 14.5 (17) | 23 (31) | 14 (14) | 0.6 | 0.59 |
| CRP, mg/dL˜ | 1.5 (4) | 0.4 (0.6) | 1.7 (2) | 0.65 (1) | 1.8 (3) | 0.64 (0.8) | 0.4 | 0.001* |
| ASDAS-CRP˜ | 3.6 (0.8) | 1.9 (1) | 3.4 (0.9) | 2 (1.2) | 3.4 (0.8) | 1.9 (1.4) | 0.4 | 0.23 |
| BASDAI score˜ | 5.7 (2.6) | 2.4 (4.5) | 5.6 (3.3) | 2.8 (3.1) | 5.6 (3.2) | 2.4 (3.3) | 1 | 0.31 |
| BASFI score˜ | 5.4 (4) | 2 (4) | 4.5 (4) | 3 (4) | 6.5 (3) | 3.9 (4.5) | 0.1 | 0.002* |
| BASFI score > 4, n (%) | 29 (59) | 23 (25) | 29 (56) | 32 (32) | 27 (75) | 36 (46) | 0.1 | 0.014* |
| ASAS PR, n (%) | 26 (28) | 15 (15) | 17 (22) | 0.09 | ||||
*p <0.05, ˚mean ± SD, ˜median (IQR) SD: Standard deviation; IQR: Inter-quartile range BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BMI: Body mass index; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; ASAS PR: Assessment in SpondyloArthritis International Society partial remission; ASDAS: Ankylosing spondylitis disease activity score